At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
In Brief
A Phase 1 clinical trial evaluating Pembrolizumab and Maraviroc for Metastatic Colorectal Cancer and MSS. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer, MSS
CountriesGermany
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartApr 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedSep 7, 2017
Enrollment StartApr 1, 2018
Primary CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.8 years ago
Interventions
Pembrolizumabbiological
Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
Maravirocdrug
Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)